Sildenafil for pulmonary arterial hypertension: when blue turns into white

Bibliography

• RUBIN LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):4S-6S.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, GALIE N, RUBIN LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):5S-12S.
   PubMed Web of Science ®Google Scholar
• D’ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. (1991) 115(5):343-349.
   PubMed Web of Science ®Google Scholar
• BARST RJ, MCGOON M, TORBICKI A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):40S-47S.
   PubMed Web of Science ®Google Scholar
• MCGOON M, GUTTERMAN D, STEEN V et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):14S-34S.
   PubMed Web of Science ®Google Scholar
• GALIE N, TORBICKI A, BARST R et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur. Heart J. (2004) 25(24):2243-2278.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):70-75.
   PubMed Web of Science ®Google Scholar
• GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1995) 333(4):214-221.
   PubMed Web of Science ®Google Scholar
• GIAID A, YANAGISAWA M, LANGLEBEN D et al.: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1993) 328(24):1732-1739.
   PubMed Web of Science ®Google Scholar
• RUNO JR, LOYD JE: Primary pulmonary hypertension. Lancet (2003) 361(9368):1533-1544.
   PubMed Web of Science ®Google Scholar
• PROVENCHER S, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin. Pharmacother. (2005) 6(8):1337-1348.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):35S-62S.
   PubMed Web of Science ®Google Scholar
• RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):76-81.
   PubMed Web of Science ®Google Scholar
• SITBON O, HUMBERT M, JAIS X et al.: Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 111(23):3105-3111.
   PubMed Web of Science ®Google Scholar
• FUSTER V, STEELE PM, EDWARDS WD et al.: Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation (1984) 70(4):580-587.
   PubMed Web of Science ®Google Scholar
• OGATA M, OHE M, SHIRATO K, TAKISHIMA T: Effects of a combination therapy of anticoagulant and vasodilator on the long-term prognosis of primary pulmonary hypertension. Jpn. Circ. J. (1993) 57(1):63-69.
   PubMedGoogle Scholar
• Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann. Intern. Med. (1980) 93(3):391-398.
   PubMed Web of Science ®Google Scholar
• Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet (1981) 1(8222):681-686.
   PubMed Web of Science ®Google Scholar
• RICH S, SEIDLITZ M, DODIN E et al.: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest (1998) 114(3):787-792.
   PubMed Web of Science ®Google Scholar
• TUDER RM, COOL CD, GERACI MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. (1999) 159(6):1925-1932.
   PubMed Web of Science ®Google Scholar
• BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. (2000) 132(6):425-434.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, MCGOON MD et al.: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121(6):409-415.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN VV, GENTHNER DE, PANELLA MM, RICH S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. (1998) 338(5):273-277.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SM, OUDIZ RJ, CAO T et al.: Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J. Am. Coll. Cardiol. (1997) 30(2):343-349.
   PubMed Web of Science ®Google Scholar
• SITBON O, HUMBERT M, NUNES H et al.: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. (2002) 40(4):780-788.
   PubMed Web of Science ®Google Scholar
• BARST RJ, MCGOON M, MCLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(12):2119-2125.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, SCHWARZE M, EHLERDING S et al.: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N. Engl. J. Med. (2000) 342(25):1866-1870.
   PubMed Web of Science ®Google Scholar
• OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347(5):322-329.
   PubMed Web of Science ®Google Scholar
• OPITZ CF, WENSEL R, WINKLER J et al.: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur. Heart J. (2005) 26(18):1895-1902.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804.
   PubMed Web of Science ®Google Scholar
• RUBENS C, EWERT R, HALANK M et al.: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest (2001) 120(5):1562-1569.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, WEBB DJ: Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. (1998) 16(8):1081-1098.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN VV, SITBON O, BADESCH DB et al.: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. (2005) 25(2):244-249.
   PubMed Web of Science ®Google Scholar
• GALIE N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46(3):529-535.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RICH S, WIDLITZ A et al.: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 121(6):1860-1868.
   PubMed Web of Science ®Google Scholar
• DUNKERN TR, HATZELMANN A: The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell. Signal. (2005) 17(3):331-339.
   PubMed Web of Science ®Google Scholar
• WHARTON J, STRANGE JW, MOLLER GM et al.: Antiproliferative effects of phosphodiesterase Type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. (2005) 172(1):105-113.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS ED: The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail. Rev. (2003) 8(1):5-21.
   PubMedGoogle Scholar
• LADHA F, BONNET S, EATON F et al.: Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med. (2005) 172(6):750-756.
   PubMed Web of Science ®Google Scholar
• TANTINI B, MANES A, FIUMANA E et al.: Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res. Cardiol. (2005) 100(2):131-138.
   PubMed Web of Science ®Google Scholar
• TURKO IV, BALLARD SA, FRANCIS SH, CORBIN JD: Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol. Pharmacol. (1999) 56(1):124-130.
   PubMed Web of Science ®Google Scholar
• KLINGER JR, THAKER S, HOUTCHENS J et al.: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest (2006) 129(2):417-425.
   PubMed Web of Science ®Google Scholar
• PRESTON IR, HILL NS, GAMBARDELLA LS, WARBURTON RR, KLINGER JR: Synergistic effects of ANP and sildenafil on cGMP levels and amelioration of acute hypoxic pulmonary hypertension. Experimental Biology and Medicine (2004) 229(9):920-925.
   Web of Science ®Google Scholar
• ZHAO L, MASON NA, STRANGE JW, WALKER H, WILKINS MR: Beneficial Effects of Phosphodiesterase 5 Inhibition in Pulmonary Hypertension Are Influenced by Natriuretic Peptide Activity. Circulation (2003) 107(2):234-237.
   PubMed Web of Science ®Google Scholar
• PAUL GA, GIBBS JSR, BOOBIS AR, ABBAS A, WILKINS MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. (2005) 60(1):107-112.
   PubMed Web of Science ®Google Scholar
• CHEITLIN MD, HUTTER AM Jr, BRINDIS RG et al.: Use of sildenafil (viagra) in patients with cardiovascular disease. Circulation (1999) 99(1):168-177.
   PubMed Web of Science ®Google Scholar
• GILLIES HC, ROBLIN D, JACKSON G: Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int. J. Cardiol. (2002) 86(2-3):131-141.
   PubMed Web of Science ®Google Scholar
• ZHAO L, MASON NA, MORRELL NW et al.: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation (2001) 104(4):424-428.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44(7):1488-1496.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. (2002) 136(7):515-522.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, WIEDEMANN R, ROSE F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet (2002) 360(9337):895-900.
   PubMed Web of Science ®Google Scholar
• KUHN KP, WICKERSHAM NE, ROBBINS IM, BYRNE DW: Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp. Lung Res. (2004) 30(2):135-145.
   PubMed Web of Science ®Google Scholar
• LEPORE JJ, MAROO A, BIGATELLO LM et al.: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest (2005) 127(5):1647-1653.
   PubMed Web of Science ®Google Scholar
• LEUCHTE HH, SCHWAIBLMAIR M, BAUMGARTNER RA et al.: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest (2004) 125(2):580-586.
   PubMed Web of Science ®Google Scholar
• MICHELAKIS E, TYMCHAK W, LIEN D et al.: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105(20):2398-2403.
   PubMed Web of Science ®Google Scholar
• WILKENS H, GUTH A, KONIG J et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation (2001) 104(11):1218-1222.
   PubMed Web of Science ®Google Scholar
• CHOCKALINGAM A, GNANAVELU G, VENKATESAN S et al.: Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int. J. Cardiol. (2005) 99(1):91-95.
   PubMed Web of Science ®Google Scholar
• SHETH A, PARK JE, ONG YE, HO TB, MADDEN BP: Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. Vascul. Pharmacol. (2005) 42(2):41-45.
   PubMedGoogle Scholar
• BHARANI A, MATHEW V, SAHU A, LUNIA B: The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J. (2003) 55(1):55-59.
   PubMedGoogle Scholar
• SASTRY BK, NARASIMHAN C, REDDY NK, RAJU BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. (2004) 43(7):1149-1153.
   PubMed Web of Science ®Google Scholar
• GALIE N, MANES A, FARAHANI KV et al.: Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 14(9):713-717.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, ROSE F, SCHERMULY RT et al.: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 42(1):158-164.
   PubMed Web of Science ®Google Scholar
• KOTHARI SS, DUGGAL B: Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. (2002) 54(4):404-409.
   PubMedGoogle Scholar
• MICHELAKIS ED, TYMCHAK W, NOGA M et al.: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 108(17):2066-2069.
   PubMed Web of Science ®Google Scholar
• MIKHAIL GW, PRASAD SK, LI W et al.: Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur. Heart J. (2004) 25(5):431-436.
   PubMed Web of Science ®Google Scholar
• SASTRY BK, NARASIMHAN C, REDDY NK et al.: A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J. (2002) 54(4):410-414.
   PubMedGoogle Scholar
• GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
   PubMed Web of Science ®Google Scholar
• MACHADO RF, MARTYR S, KATO GJ et al.: Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. (2005) 130(3):445-453.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, FAULENBACH C, GOLPON H et al.: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. (2004) 24(6):1007-1010.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, MARKEVYCH I, SPIEKERKOETTER E, WELTE T, NIEDERMEYER J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur. Respir. J. (2005) 26(5):858-863.
   PubMed Web of Science ®Google Scholar
• HUMPL T, REYES JT, HOLTBY H, STEPHENS D, ADATIA I: Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation (2005) 111(24):3274-3280.
   PubMed Web of Science ®Google Scholar
• KARATZA AA, BUSH A, MAGEE AG: Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. Int. J. Cardiol. (2005) 100(2):267-273.
   PubMed Web of Science ®Google Scholar
• LEE AJ, CHIAO TB, TSANG MP: Sildenafil for pulmonary hypertension. Ann. Pharmacother. (2005) 39(5):869-884.
   PubMedGoogle Scholar
• BARST RJ: PDGF signaling in pulmonary arterial hypertension. J. Clin. Invest. (2005) 115(10):2691-2694.
   PubMed Web of Science ®Google Scholar